Iovance Biotherapeutics Inc
NASDAQ:IOVA
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Price:
10.88 USD
-0.78%
Market Closed
Updated:
May 14, 2024
Section:
Relative Value
The Relative Value of one
IOVA
stock under the Base Case scenario is
18.02
USD.
Compared to the current market price of 10.88 USD,
Iovance Biotherapeutics Inc
is
Undervalued by 40%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IOVA
Relative Value
Base Case
18.02
USD
Undervaluation 40%
Valuation Multiples
Multiples Across Competitors
IOVA Competitors Multiples
Iovance Biotherapeutics Inc Competitors
Iovance Biotherapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
3B USD | 1 596.1 | -6.8 | -6.1 | -5.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284.8B USD | 5.2 | 59.1 | 12.8 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.5B USD | 5.6 | 44 | 18.6 | 30.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 11.2 | 30.6 | 24.7 | 25.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.7B USD | 8.2 | 27.9 | 22.6 | 25 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.2B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.2B USD | 3.1 | 173.9 | 7 | 9.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48.1B USD | 9.3 | -8.1 | -8.8 | -7.8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 3.4 | 28.1 | 14.3 | 17.9 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.5T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
